<DOC>
	<DOCNO>NCT03001557</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled , parallel-group study lemborexant ( 4 dose level ) placebo take daily 4 week approximately 125 male female participant , age 65 90 year , mild moderate Alzheimer 's disease dementia ( AD-D ) complain disrupted sleep multiple awakening night along frequent period fall asleep day impact quality life participant . The study design determine whether least one dose lemborexant superior placebo base change baseline actigraphy Sleep Efficiency actigraphy Wake Efficiency last week 4 week treatment participant Irregular Sleep-Wake Rhythm Disorder AD-D .</brief_summary>
	<brief_title>Study Lemborexant Irregular Sleep-Wake Rhythm Disorder Mild Moderate Alzheimer 's Disease Dementia</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<criteria>Inclusion Criteria Participants : Male female , age 65 90 year time inform consent Able provide inform consent . If participant lack capacity consent investigator 's opinion , participant 's assent obtain , require accordance local law , regulation custom , write informed consent legal representative obtain ( capacity consent definition legal representative determine accordance applicable local law regulation ) . Documentation diagnosis Alzheimer 's disease dementia ( ADD ) basis National Institute Aging/Alzheimer 's Association Diagnostic Guidelines Mini Mental State Examination ( MMSE ) 18 26 Screening Meets criteria Circadian Rhythm Sleep Disorder , Irregular SleepWake Type ( Diagnostic Statistical Manual Mental Disorders 5th edition [ DSM5 ] ) 10th revision International Classification Diseases , follow : Complaint participant difficulty sleep night and/or excessive daytime sleepiness associate multiple irregular sleep bout 24hour period Frequency complaint sleep wake fragmentation &gt; 3 day per week Duration complaint sleep wake fragmentation ≥3 month During Screening Period , mean actigraphy Sleep Efficiency &lt; 75 % within defined nocturnal sleep period mean actigraphy Wake Efficiency &lt; 87.5 % defined wake period Confirmation sufficient duration time bed night , define least 7 hour determine sleep log Confirmation actigraphy combination sleep bout &gt; 10 minute wake period plus wake bout &gt; 10 minute sleep period , total least 4 bout per 24hour period , ≥3 day per week Ambulatory living community residence classify skilled nursing facility Willing start behavioral treatment program sleep wake difficulty start new treatment symptom ADD participation study Has reliable competent caregiver accompany participant study visit , administer study medication nightly basis provide information status participant For participant take cholinesterase inhibitor and/or memantine , dose regimen must stable least 3 month . Inclusion Criteria Caregivers : Able provide inform consent Lives home participant approximate schedule participant Able meet caregiver requirement Willing provide information himself/herself regard sleep quality caregiver burden Exclusion Criteria Participants : A diagnosis vascular dementia , dementia follow multiple stroke , synucleinopathy/Lewy body disorder . This include Dementia Lewy Bodies Parkinson 's disease without dementia . A current diagnosis moderate severe obstructive sleep apnea ( OSA ) , current use continuous positive airway pressure even mild severity OSA , restless legs syndrome , periodic limb movement disorder ( awakening ) , narcolepsy An ApneaHypopnea Index equivalent ≥15 events/hour diagnostic sleep study conduct prior Baseline within 6 month Screening A clinically significant movement disorder would affect differentiation sleep wake actigraphy analytic algorithm Current symptoms history past year Rapid Eye Movement Behavior Disorder sleeprelated violent behavior Probable Major Depression , evidence score &gt; 10 Cornell Scale Depression Dementia Screening Unable tolerate wear actigraph . At minimum , participant must able wear actigraph 5 complete day 7 day ' data . A day consider complete long data 90 % 24hour period scorable . Excessive caffeine use opinion investigator contribute participant 's Irregular SleepWake Rhythm Disorder ( ISWRD ) History drug alcohol dependency abuse within approximately previous 2 year Reports habitually consume 14 drink contain alcohol per week habitually consume alcohol within 3 hour bedtime unwilling limit alcohol intake 2 few drink per day forego alcohol within 3 hour bedtime duration his/her participation study Known human immunodeficiency virus positive Active viral hepatitis ( B C ) demonstrate positive serology Screening A prolonged QTcF interval ( QTcF &gt; 450 millisecond [ m ] ) demonstrate repeat electrocardiogram ( ECG ) Screening ( repeat initial ECG indicate QTcF interval &gt; 450 m ) evidence bundle branch block Current evidence clinically significant disease opinion investigator ( ) could affect participant 's safety interfere study assessment Any history medical psychiatric condition ADD opinion investigator ( ) could affect participant 's safety interfere study assessment History malignancy within previous 5 year except adequately treat basal cell squamous cell skin cancer cervical carcinoma situ Any suicidal ideation intent without plan , time within 6 month Screening , indicate answer `` Yes '' question 4 5 Suicidal Ideation section electronic ColumbiaSuicide Severity Rating Scale ( eCSSRS ) Any lifetime suicidal behavior base eCSSRS History violence toward caregiver others Scheduled surgery study Used prohibit prescription overthecounter concomitant medication within 1 week 5 halflives , whichever longer , start actigraphy Screening Used modality treatment ISWRD Screening Randomization , include phototherapy ( light therapy ) Failed treatment Belsomra® ( efficacy and/or safety ) follow treatment appropriate dose adequate duration opinion investigator Transmeridian travel across 3 time zone Screening Randomization , plan travel across 3 time zone study Hypersensitivity lemborexant excipients Currently enrol another clinical trial Used investigational drug device inform consent ( i.e. , within 30 day 5× investigational drug halflife whichever longer 6 month potential diseasemodifying drug ) Previously participate clinical trial lemborexant</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Mild Moderate Alzheimer 's Disease Dementia</keyword>
	<keyword>sleep</keyword>
	<keyword>circadian rhythm</keyword>
</DOC>